Medicine supply chain issues have impacted up to 6.4 million prescriptions per month in 2026 so far, the National Pharmacy Association (NPA) has found.
The figures, published today, are based on the NPA’s analysis of the number of Medicine Supply Notifications (MSN) issued by the Department of Health and Social Care (DH) this year.
The body has also called upon the new Health Secretary Yvette Cooper to publish an “urgent action plan” in response to ongoing medicine shortages, stressing that disruption to drug supply chains “blights pharmacies daily and causes undue stress and anxiety to patients”.
“Serious risk to safety”
According to the NPA, there are currently 14 active MSNs, with Ramipril, co-codamol and hormone replacement therapy (HRT) medication Estradot all experiencing shortages throughout 2026.
MSNs are issued when a medicine is no longer in supply or there are supply constraints in place.
The body warned that while a medication shortage is “frustrating” for most patients, for those taking medicines such as insulin, Creon and Nabilone, shortages can pose “a serious risk” to safety.
Read more: ‘Deeply depressing’: SSPs for Creon and Estradot extended again
It also highlighted the record-breaking number of price concessions issued by the DH, with 245 in October 2026, compared to 100 in October 2025.
And it urged the government to publish the outcome of its consultation on allowing pharmacists to make medicine substitutions, which concluded almost a year ago.
“A perfect storm”
NPA chair Olivier Picard described the figures as “shocking” and said the sector is “looking at a perfect storm of medicine supply challenges coupled with soaring prices, with pharmacy owners all too often footing the bill of our medicines”.
“Despite government claims that the situation with medicine supply may be improving, this simply does not match the reality that pharmacies and the patients they serve are seeing on the ground,” he added.
Read more: ‘Alarming’: Drug price concessions hit fifth record high this year
Picard called on the new secretary of state to “grip this problem head on” by “overturning mad rules that stop pharmacists from making any changes to a prescription when a medicine is out of stock, forcing a patient to go back to their GP”.
It comes after the DH further extended the serious shortage protocols for pancreatic enzyme replacement therapy drug Creon and HRT medication Estradot in October.
And it follows drug price concessions hitting a new record high in October and for the fifth time this year, according to Community Pharmacy England.

